These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 10979311)

  • 21. CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile.
    Rougier P; Bugat R
    Semin Oncol; 1996 Feb; 23(1 Suppl 3):34-41. PubMed ID: 8633252
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma.
    Poon D; Chowbay B; Cheung YB; Leong SS; Tan EH
    Cancer; 2005 Feb; 103(3):576-81. PubMed ID: 15612023
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and toxicity of irinotecan in patients with colorectal cancer.
    Rothenberg ML
    Semin Oncol; 1998 Oct; 25(5 Suppl 11):39-46. PubMed ID: 9786315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Irinotecan/thalidomide in metastatic colorectal cancer.
    Govindarajan R
    Oncology (Williston Park); 2002 Apr; 16(4 Suppl 3):23-6. PubMed ID: 12014864
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single-agent irinotecan for recurrent/metastatic colorectal cancer: a retrospective analysis.
    Sanli UA; Karabulut B; Uslu R; Korkut M; Goker E
    Med Princ Pract; 2006; 15(4):288-92. PubMed ID: 16763396
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of CPT-11 (irinotecan) as a single agent in metastatic colorectal cancer.
    Shimada Y; Rougier P; Pitot H
    Eur J Cancer; 1996; 32A Suppl 3():S13-7. PubMed ID: 8943660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Weekly irinotecan in patients with metastatic colorectal cancer failing 5-fluorouracil-based chemotherapy: efficacy and prognostic factors.
    Karaoğlu A; Yalcin S; Tekuzman G; Kars A; Celik I; Güler N; Ozişik Y; Türker A; Barişta I; Güllü I
    Tumori; 2003; 89(2):141-5. PubMed ID: 12841660
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer.
    Meyerhardt JA; Kwok A; Ratain MJ; McGovren JP; Fuchs CS
    J Clin Oncol; 2004 Apr; 22(8):1439-46. PubMed ID: 15084617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FDA approves irinotecan as first-line therapy for colorectal cancer.
    Oncology (Williston Park); 2000 May; 14(5):652, 654. PubMed ID: 10853457
    [No Abstract]   [Full Text] [Related]  

  • 30. High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer.
    Ychou M; Raoul JL; Desseigne F; Borel C; Caroli-Bosc FX; Jacob JH; Seitz JF; Kramar A; Hua A; Lefebvre P; Couteau C; Merrouche Y
    Cancer Chemother Pharmacol; 2002 Nov; 50(5):383-91. PubMed ID: 12439596
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Application and recent research progress of irinotecan in treatment of advanced colorectal cancer].
    Guan ZZ
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):718-9. PubMed ID: 17274384
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU).
    Van Cutsem E; Cunningham D; Ten Bokkel Huinink WW; Punt CJ; Alexopoulos CG; Dirix L; Symann M; Blijham GH; Cholet P; Fillet G; Van Groeningen C; Vannetzel JM; Levi F; Panagos G; Unger C; Wils J; Cote C; Blanc C; Hérait P; Bleiberg H
    Eur J Cancer; 1999 Jan; 35(1):54-9. PubMed ID: 10211088
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Irinotecan-based chemotherapy in a metastatic colorectal cancer patient under haemodialysis for chronic renal dysfunction: two cases considered.
    Vénat-Bouvet L; Saint-Marcoux F; Lagarde C; Peyronnet P; Lebrun-Ly V; Tubiana-Mathieu N
    Anticancer Drugs; 2007 Sep; 18(8):977-80. PubMed ID: 17667606
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of advanced or recurrent colorectal cancer with irinotecan in Japan and elsewhere.
    Sato T; Hatate K; Ikeda A; Yamanashi T; Ozawa H; Onosato W; Nakamura T; Ihara A; Watanabe M
    Expert Opin Pharmacother; 2008 May; 9(7):1223-8. PubMed ID: 18422478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment.
    Dopeso H; Mateo-Lozano S; Elez E; Landolfi S; Ramos Pascual FJ; Hernández-Losa J; Mazzolini R; Rodrigues P; Bazzocco S; Carreras MJ; Espín E; Armengol M; Wilson AJ; Mariadason JM; Ramon Y Cajal S; Tabernero J; Schwartz S; Arango D
    Clin Cancer Res; 2010 Apr; 16(8):2375-82. PubMed ID: 20371676
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activity of irinotecan, cisplatin and dacarbazine (CPD) combination in previously treated patients with advanced colorectal carcinoma.
    Akbulut H; Icli F; Yalcin B; Demirkazik A; Onur H; Buyukcelik A; Utkan G
    Exp Oncol; 2004 Jun; 26(2):149-52. PubMed ID: 15273666
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Second-line chemotherapy with low-dose CPT-11 and cisplatin for colorectal cancer resistant to 5-FU-based chemotherapy.
    Yoshimatsu K; Kato H; Ishibashi K; Hashimoto M; Umehara A; Yokomizo H; Yoshida K; Fujimoto T; Iwasaki K; Ogawa K
    Cancer Chemother Pharmacol; 2003 Dec; 52(6):465-8. PubMed ID: 12920569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CPT-11 in gastrointestinal cancer.
    Bleiberg H
    Eur J Cancer; 1999 Mar; 35(3):371-9. PubMed ID: 10448285
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer.
    Fujita K; Kubota Y; Ishida H; Sasaki Y
    World J Gastroenterol; 2015 Nov; 21(43):12234-48. PubMed ID: 26604633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group.
    Pappo AS; Lyden E; Breitfeld P; Donaldson SS; Wiener E; Parham D; Crews KR; Houghton P; Meyer WH;
    J Clin Oncol; 2007 Feb; 25(4):362-9. PubMed ID: 17264331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.